Direxion Shares ETF Trust Direxion Daily Crypto Industry Bear 1X Shares (ARCA: REKT)

에 대한 최신 뉴스 Direxion Shares ETF Trust Direxion Daily Crypto Industry Bear 1X Shares (ARCA:REKT)

Direxion Shares ETF Trust Direxion Daily Crypto Industry Bear 1X Shares

The Fund, under normal circumstances, invests at least 80 percent of the Funds net assets (plus borrowing for investment purposes) in financial instruments, including swap agreements, futures contracts, or short positions, that, in combination, provide 1X daily inverse (opposite) or short exposure to the Index or to exchange-traded funds (ETFS) that track the Index, consistent with the Funds investment objective.

Dreyfus Govt Cash Man Ins

Goldman Sachs Fin Gov 465 Institut

Gs Financial Square Treasury Instruments Fund

Direxion Daily Crypto Industry Bear 1X Shares

Untitled design(201)

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Long Ideas

Sector ETFs

Specialty ETFs

Commodities

Exclusives

Markets

Trading Ideas

Interview

ETFs

$BTC

LMBO

REKT

디렉시온(Direxion)의 CEO 더글라스 요네스(Douglas Yones)는 암호화폐와 상품이 지속적인 거시경제 불확실성으로부터 어떻게 혜택을 받을 수 있는지에 대한 통찰을 벤징가와 공유했다.

독점: 디렉시온의 CEO, 암호화폐와 상품이 2025년 변동성의 중심에 위치할 것으로 전망

Truist Securities analyst Joel Fishbein maintains Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>) with a Buy and lowers the price target from $48 to $45.

News

Price Target

Analyst Ratings

TENB

Truist Securities Maintains Buy on Tenable Holdings, Lowers Price Target to $45

Biotech

General

TOVX

Theriva Biologics Reports Results From Second Independent Data Monitoring Committee Meeting For VIRAGE, Phase 2b Trial Of VCN-01 With Chemotherapy In Metastatic Pancreatic Ductal Adenocarcinoma

Earnings

SIEB

Siebert FY24 EPS $0.33 Up From $0.21 YoY; Revenue $83.9M Up From $71.5M YoY

Truist Securities analyst Joel Fishbein maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Buy and lowers the price target from $213 to $205.

PANW

Truist Securities Maintains Buy on Palo Alto Networks, Lowers Price Target to $205

<ul>
<li>Increased survival and reduced major adverse cardiac and cerebrovascular events (MACCE) observed study-wide, despite primary composite efficacy endpoint not reaching statistical significance</li>
<li>Statistically significant improvement in composite outcome measure comprised of survival, MACCE, and quality of life seen in patients suffering from active heart stress (those with elevated NTproBNP and BNP biomarkers) treated with CardiAMP Cell Therapy</li>
<li>Patient improvements through two years suggest single dose of CardiAMP therapy offers durable benefits</li>
</ul>
SUNNYVALE, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=yO0hnwnvi7iEwRN-J_Dfer2Ck-H9o0KzxkQybQkR2_kpMRKPiIRms5-1EPJ90iC7tT54m56uZdNvNbdHehw7TnEwvZJLEsyczcpNFqYzFtM=">BioCardia, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>),a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced&nbsp;two-year outcomes from the double-blind randomized placebo-controlled Phase 3 CardiAMP-HF study of its <a href="https://www.globenewswire.com/Tracker?data=hL7ounNvczJizOwVS6OFHrH1v1ZDPT4mNBAPrU_HIQBwJCOG9k9Iw8tKPO5pi2KklMG0HhnngWT8uWMgJRCPrb3hm3-bzdW7gV1ZAtKspEly1LuISpKaumcGRqwg1i7ocnbru13PFIDqgDjvVFKJzA==">CardiAMP</a> autologous minimally invasive cell therapy for the treatment of ischemic heart failure in patients with reduced ejection fraction (HFrEF).&nbsp;Results were presented yesterday as a late-breaking clinical trial at the American College of Cardiology's Annual Scientific Session and Expo by co-principal investigator Amish N. Raval, MD, FACC, professor of medicine at the University of Wisconsin School of Medicine and Public Health.

BCDA

Biocardia Phase 3 CardiAMP-HF Trial Of Novel Cardiac Cell Therapy For Ischemic Heart Failure Shows Increased Survival, Decreased Cardiac Events, And Improved Quality Of Life At 2-Years

Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) reported quarterly losses of $(2.23) per share which missed the analyst consensus estimate of $(0.42) by 430.95 percent. This is a 271.67 percent decrease over losses of $(0.60) per share from the same period last year.

Earnings Misses

MNPR

Monopar Therapeutics Q4 2024 GAAP EPS $(2.23) Misses $(0.42) Estimate

ALPS ETF Trusthen & Steers Global Realty Majors ETF

GRI Bio Expands Intellectual Property Portfolio With Granting of Two Global Patents in Europe and Japan

Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) reported quarterly losses of $(2.23) per share. This is a 271.67 percent decrease over losses of $(0.60) per share from the same period last year.

Monopar Therapeutics Q4 EPS $(2.23) Down From $(0.60) YoY

Jones Trading analyst Stephen Glagola initiates coverage on TeraWulf (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WULF#NASDAQ">WULF</a>) with a Buy rating and announces Price Target of $4.

Initiation

WULF

Jones Trading Initiates Coverage On TeraWulf with Buy Rating, Announces Price Target of $4

Truist Securities analyst Junaid Siddiqui maintains CyberArk Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYBR#NASDAQ">CYBR</a>) with a Buy and lowers the price target from $450 to $425.

CYBR

Truist Securities Maintains Buy on CyberArk Software, Lowers Price Target to $425

CRIS

Curis Says Orphan Drug Designation For PCNSL Granted In U.S. And EU

ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) reported quarterly losses of $(56.94) per share which missed the analyst consensus estimate of $(47.46) by 19.97 percent.

NDRA

ENDRA Life Sciences FY 2024 GAAP EPS $(56.94) Misses $(47.46) Estimate

Amarin Corporation plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMRN#NASDAQ">AMRN</a>) today highlighted key data presentations at ACC.25 showcasing the mechanistic activity of eicosapentaenoic&nbsp;acid (EPA) on lipoprotein(a) [Lp(a)]-enriched plasma and the effects of a glucagon-like peptide-1 (GLP-1) receptor agonist in combination with EPA on the expression of proteins in endothelial cells.

AMRN

Amarin Highlights Recent Data Presented At ACC.25 Evaluating Mechanistic Effects Of Eicosapentaenoic Acid In Lp(a)-Enriched Plasma And In Combination With GLP-1 Agonist

Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) reported quarterly losses of $(4.83) per share which missed the analyst consensus estimate of $(0.23) by 2000 percent. This is a 78.1 percent increase over losses of $(22.05) per share from the same period last year.

ENVB

Enveric Biosciences Q4 2024 GAAP EPS $(4.83) Misses $(0.23) Estimate

Workhorse Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKHS#NASDAQ">WKHS</a>) shares are trading <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">higher in premarket on Monday</a> after the fiscal year 2024 earnings report.
The company reported a FY24 sales <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44558026/workhorse-group-reports-full-year-2024-results" rel="noreferrer noopener">decline of 49.5% year-on-year</a> to $6.616 million, missing the analyst consensus estimate of $7.750 million.
The $6.5 million decrease in sales was primarily due to lower W4 CC truck sales compared with the same period a year ago.
EPS loss of $51.69 <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">missed the analyst</a> consensus loss estimate of $30.44.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/03/44558573/president-trumps-sons-partner-with-hut-8-to-unveil-american-bitcoin-for-large-scale-bitcoin-mining" rel="noreferrer noopener">President Trump&#8217;s Sons Partner With Hut 8 To Unveil American Bitcoin For Large-Scale Bitcoin Mining</a>
Selling, general, and administrative expenses for the full year 2024 were $42.5 million, a decrease of $13.1 million compared to $55.6 million in 2023.
The decline in expenses were primarily driven by a $8.2 million decrease in employee compensation and related expenses due to a lower headcount.
Loss from operations for the year narrowed to $73.88 million from a loss of $105.3 million last year. The company held $4.64 million in cash and equivalents as of December 31, 2024.
&#8220;We took significant cost reduction and other actions throughout 2024 to lower our operating cash burn and executed a financing arrangement with an institutional investor to provide us near term liquidity, as we navigated a weaker than expected demand environment,&#8221; said CFO Bob Ginnan.
&#8220;Looking forward, we continue to focus on seeking additional opportunities to reduce costs and cash use to ensure we have the financial runway to achieve our strategic goals.&#8221;&nbsp;
Price Action: WKHS shares traded higher by 10.8% at $2.149 in premarket at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/03/44532830/rocket-lab-joins-us-space-forces-5-6-billion-launch-program-stock-soars" target="_blank" rel="noreferrer noopener">Rocket Lab Joins US Space Force&#8217;s $5.6 Billion Launch Program</a></li>
</ul>
Photo: Shutterstock.

Equities

Movers

WKHS

Workhorse Misses On FY24 Revenue And EPS, But Cost Cuts Narrow Losses

Truist Securities analyst Joel Fishbein maintains CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) with a Buy and lowers the price target from $460 to $450.

CRWD

Truist Securities Maintains Buy on CrowdStrike Holdings, Lowers Price Target to $450

SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) ("CERo" or the "Company") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms, announces that the Company has received clearance by the U.S. Food and Drug Administration (FDA) for a second Investigational New Drug (IND) application for lead compound CER-1236 for a Phase 1 clinical trial in advanced solid tumors, specifically non-small cell lung cancer and ovarian cancer.
CERo Chief Medical Officer Robert Sikorski, M.D., Ph.D. commented, "Following the launch of our AML trial, we are now starting a second clinical study of CER-1236 to evaluate its potential in solid tumors and bring new therapeutic options to patients with ovarian and lung cancer," said Robert Sikorski, M.D., Ph.D., Chief Medical Officer of CERo. "CER-1236 is novel: the first CAR-T cell therapy to target Tim-4L and the first with phagocytic activity programmed into a T cell. Preclinical data suggest that this dual mechanism may help overcome key resistance barriers that have hampered solid tumor CAR-T trials. The FDA's collaborative role has been critical to maintaining development velocity and enabling us to operate two open trials in both hematologic and solid tumors. Taken together, this expansion reflects our belief in the therapeutic breadth and the commercial and partnering potential of CER-1236." &nbsp;

CERO

CERo Therapeutics Receives FDA Clearance For Second Investigational New Drug Application And Will Initiate Phase 1 Clinical Trial Of Lead Compound CER-1236 In Solid Tumors

<ul>
<li>Urcosimod in Phase 2 clinical trial for Neuropathic Corneal Pain shown to have Long-Term Stability</li>
<li>Urcosimod stable in single-use ampoules for more than 2½ years</li>
<li>FDA requires drug to show long-term shelf stability for approval</li>
<li>Daily administration to patients via ampoules can minimize risk of contamination</li>
</ul>
LONDON and NEW YORK, March 31, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that the Company has successfully established that urcosimod (formerly known as OK-101) has been shown to be stable for over two and a half years in single-use ampoules used for administration of the drug to patients. Urcosimod is presently in a Phase 2b, randomized, placebo-controlled, double-masked, 48-patient clinical trial to treat NCP patients.

OKYO

OKYO Pharma Announces Data In Long-Term Stability Of Urcosimod; Urcosimod In Phase 2 Clinical Trial For Neuropathic Corneal Pain Shown To Have Long-Term Stability

VNDA

Vanda Pharmaceuticals Submits An NDA To The FDA For Bysanti For The Treatments Of Acute Bipolar I Disorder And Schizophrenia

Jefferies analyst David Katz initiates coverage on Viking Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIK#NYSE">VIK</a>) with a Hold rating and announces Price Target of $45.

Jefferies Initiates Coverage On Viking Holdings with Hold Rating, Announces Price Target of $45

Screenshot 2025-02-13 at 8.36.06 AM

Crypto Fervor Is Growing, But Some Remain Cautious – Place Your Bets Either Way With LMBO Or REKT

디렉시온(Direxion)의 CEO 더글라스 요네스(Douglas Yones)는 <a href="https://www.benzinga.com/crypto">암호화폐</a>와 <a href="https://www.benzinga.com/markets/commodities">상품</a>이 <a href="https://www.benzinga.com/premium/ideas/2025-market-outlook-navigating-uncertainty-with-high-yield-strategies/">지속적인 거시경제 불확실성</a>으로부터 어떻게 혜택을 받을 수 있는지에 대한 통찰을 벤징가와 공유했다.
전통적인 시장이 불안정한 상황에도 불구하고, 요네스는 암호화폐, 특히 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)의 지속적인 상승에 대해 낙관적이다.
그는 &#8220;2024년 미국에서 자산운용 규모(AUM)가 가장 큰 새로운 ETF 세 개가 모두 비트코인 관련 ETF였으며, 이 추세는 계속될 것&#8221;이라고 말했다.
대통령 당선인 도널드 트럼프의 친암호화폐 행정부는 디지털 자산에 대한 추가 수요를 촉진하는 역할을 할 것으로 예상된다. Direxion Daily Crypto Industry Bull 2X Shares(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMBO#NYSE">LMBO</a>) 및 Direxion Daily Crypto Industry Bear 1X Shares(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/REKT#NYSE">REKT</a>)와 같은 ETF는 투자자들이 이 분야에서 성장성을 추구함에 따라 관심이 증가할 것으로 보인다.
읽어보세요: <a href="https://kr.benzinga.com/crypto/bitcoin/%ED%8A%B8%EB%9F%BC%ED%94%84-%EC%B7%A8%EC%9E%84-%EC%B2%AB%EB%82%A0-%EC%95%94%ED%98%B8%ED%99%94%ED%8F%90-%EA%B4%80%EB%A0%A8-%ED%96%89%EC%A0%95%EB%AA%85%EB%A0%B9%EC%97%90-%EC%84%9C%EB%AA%85-%EA%B0%80/" target="_blank" rel="noopener">트럼프가 첫날에 암호화폐 관련 행정명령에 서명할 수 있다: 보도</a>
<h2 class="wp-block-heading">상품을 포트폴리오 다각화 수단으로</h2>
상품은 주식과 채권을 넘어 포트폴리오를 다각화하는 방법으로 수요가 증가할 것으로 예상된다.
요네스는 &#8220;미국 주식 가치가 높은 수준에 있고 인플레이션이 여전히 지속적이기 때문에, 상품은 전체 포트폴리오 내에서 추가적인 다각화를 제공할 수 있다&#8221;고 말했다.
Direxion Auspice Broad Commodity Strategy ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COM#NYSE">COM</a>)는 그런 옵션 중 하나이다.
<h2 class="wp-block-heading">유연성을 위한 레버리지 및 인버스 ETF</h2>
트레이더들은 레버리지 및 인버스 ETF도 주목할 필요가 있다.
요네스는 &#8220;특히 레버리지 및 인버스 ETF는 시장의 상승과 하강을 탐색할 수 있는 유연한 방법을 제공한다&#8221;고 말했다.
이 ETF들은 상승 및 하강 노출을 모두 제공할 수 있어 단기 시장 변동성을 활용하려는 투자자들에게 이상적이다.
다음 읽기: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41354820/tech-sector-chaos-puts-spotlight-on-direxions-3x-leveraged-soxl-and-soxs-funds">기술 섹터 혼란이 디렉시온의 3배 레버리지 SOXL 및 SOXS 펀드에 주목하게 함</a></li>
</ul>
이미지: Shutterstock
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Direxion Shares ETF Trust Direxion Daily Crypto Industry Bear 1X Shares

뉴스

에 대한 최신 뉴스 Direxion Shares ETF Trust Direxion Daily Crypto Industry Bear 1X Shares (ARCA:REKT)

수요일, 1월 15, 2025

뉴스

파트너 / 기고자

벤징가 글로벌